연구동향 분석
박사

Development of VLP, adjuvant, micro dermal injection and those application on influenza vaccine = 바이러스 유사 입자, 면역 증강제, 미세 피부 접종법 개발 및 인플루엔자 백신에의 적용

노진용 2019년

논문상세정보
인용/피인용
' Development of VLP, adjuvant, micro dermal injection and those application on influenza vaccine = 바이러스 유사 입자, 면역 증강제, 미세 피부 접종법 개발 및 인플루엔자 백신에의 적용' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • Influenza
  • Virus-like parrticle
  • adjuvant
  • micro-needle
  • vaccine
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
275 0

0.0%

' Development of VLP, adjuvant, micro dermal injection and those application on influenza vaccine = 바이러스 유사 입자, 면역 증강제, 미세 피부 접종법 개발 및 인플루엔자 백신에의 적용' 의 참고문헌

  • Young, S.-H., J. Ye, D. G. Frazer, X. Shi and V. Castranova, 2001: Molecular mechanism of tumor necrosis factor-α production in 1→ 3-β-glucan (zymosan)-activated macrophages. J. Biol. Chem., 276, 20781-20787.
  • Yang, Z. Y., C. J. Wei, W. P. Kong, L. Wu, L. Xu, D. F. Smith and G. J. Nabel, 2007: Immunization by avian H5 influenza hemagglutinin mutants with altered receptor binding specificity. Science, 317, 825-828.
  • Xue, C., W. Wang, Q. Liu, Z. Miao, K. Liu, H. Shen, L. Lv, X. Li, X. Chen and Y. Cao, 2014: Chimeric influenza-virus-like particles containing the porcine reproductive and respiratory syndrome virus GP5 protein and the influenza virus HA and M1 proteins. Archives of virology, 159, 3043-3051.
  • World-Health-Organization, 2015: Cumulative number of confirmed human cases of avian influenza A(H5N1) reported to WHO.
  • Wischke, C., J. Zimmermann, B. Wessinger, A. Schendler, H.-H. Borchert, J. H. Peters, T. Nesselhut and D. R. Lorenzen, 2009: Poly (I: C) coated PLGA microparticles induce dendritic cell maturation. Int. J. Pharm., 365, 61-68.
  • Weldon, W. C., V. G. Zarnitsyn, E. S. Esser, M. T. Taherbhai, D. G. Koutsonanos, E. V. Vassilieva, I. Skountzou, M. R. Prausnitz and R. W. Compans, 2012: Effect of adjuvants on responses to skin immunization by microneedles coated with influenza subunit vaccine. PloS one, 7, e41501.
  • Weldon, W. C., M. P. Martin, V. Zarnitsyn, B. Wang, D. Koutsonanos, I. Skountzou, M. R. Prausnitz and R. W. Compans, 2011: Microneedle vaccination with stabilized recombinant influenza virus hemagglutinin induces improved protective immunity. Clin. Vaccine Immunol., 18, 647-654.
  • Webster, R. G., D. J. Hulse-Post, K. M. Sturm-Ramirez, Y. Guan, M. Peiris, G. Smith and H. Chen, 2007: Changing epidemiology and ecology of highly pathogenic avian H5N1 influenza viruses. Avian diseases, 51, 269-272.
  • Webster, R. G. and E. A. Govorkova, 2014: Continuing challenges in influenza. Annals of the New York Academy of Sciences, 1323, 115-139.
  • Wang, W., X. Chen, C. Xue, Y. Du, L. Lv, Q. Liu, X. Li, Y. Ma, H. Shen and Y. Cao, 2012: Production and immunogenicity of chimeric virus-like particles containing porcine reproductive and respiratory syndrome virus GP5 protein. Vaccine, 30, 7072-7077.
  • Wang, J., B. Li and M. X. Wu, 2015: Effective and lesion-free cutaneous influenza vaccination. Proc. Natl. Acad. Sci. U. S. A., 112, 5005-5010.
  • Wang, B.-Z., H. S. Gill, C. He, C. Ou, L. Wang, Y.-C. Wang, H. Feng, H. Zhang, M. R. Prausnitz and R. W. Compans, 2014: Microneedle delivery of an M2e- TLR5 ligand fusion protein to skin confers broadly cross-protective influenza immunity. J. Controlled Release, 178, 1-7.
  • Vogelbruch, M., B. Nuss, M. K rner, A. Kapp, P. Kiehl and W. Bohm, 2000: Aluminium-induced granulomas after inaccurate intradermal hyposensitization injections of aluminium-adsorbed depot preparations. Allergy, 55, 883-887.
  • UYEKI, T. M. 2009. Human infection with highly pathogenic avian influenza A (H5N1) virus: review of clinical issues. Clin Infect Dis 49: 279-290.
  • Tritto, E., F. Mosca and E. De Gregorio, 2009: Mechanism of action of licensed vaccine adjuvants. Vaccine, 27, 3331-3334.
  • Tretyakova, I., M. B. Pearce, R. Florese, T. M. Tumpey and P. Pushko, 2013: Intranasal vaccination with H5, H7 and H9 hemagglutinins co-localized in a virus-like particle protects ferrets from multiple avian influenza viruses. Virology, 442, 67-73.
  • Toyoda, T., B. Gotoh, T. Sakaguchi, H. Kida and Y. Nagai, 1988: Identification of amino acids relevant to three antigenic determinants on the fusion protein of Newcastle disease virus that are involved in fusion inhibition and neutralization. Journal of virology, 62, 4427-4430.
  • Tiensin, T., P. Chaitaweesub, T. Songserm, A. Chaisingh, W. Hoonsuwan, C. Buranathai, T. Parakamawongsa, S. Premashthira, A. Amonsin, M. Gilbert, M. Nielen and A. Stegeman, 2005: Highly pathogenic avian influenza H5N1, Thailand, 2004. Emerging infectious diseases, 11, 1664-1672.
  • Terregino, C., R. De Nardi, V. Guberti, M. Scremin, E. Raffini, A. M. Martin, G. Cattoli, L. Bonfanti and I. Capua, 2007: Active surveillance for avian influenza viruses in wild birds and backyard flocks in Northern Italy during 2004 to 2006. Avian pathology : journal of the W.V.P.A, 36, 337-344.
  • Szyszko, E., K. Brokstad, R. Cox, A. O. Hovden, A. Madhun and L. Haaheim, 2006: Impact of influenza vaccine formulation with a detailed analysis of the cytokine response. Scand. J. Immunol., 64, 467-475.
  • Swayne, D. E., 2009: Avian influenza vaccines and therapies for poultry. Comparative immunology, microbiology and infectious diseases, 32, 351- 363.
  • Svitek, N., P. A. Rudd, K. Obojes, S. Pillet and V. von Messling, 2008: Severe seasonal influenza in ferrets correlates with reduced interferon and increased IL-6 induction. Virology, 376, 53-59.
  • Sun, J., R. Madan, C. L. Karp and T. J. Braciale, 2009: Effector T cells control lung inflammation during acute influenza virus infection by producing IL-10. Nat. Med., 15, 277-284.
  • Sun, H., J. Pu, Y. Wei, Y. Sun, J. Hu, L. Liu, G. Xu, W. Gao, C. Li, X. Zhang, Y. Huang, K. C. Chang, X. Liu and J. Liu, 2016: Highly Pathogenic Avian Influenza H5N6 Viruses Exhibit Enhanced Affinity for Human Type Sialic Acid Receptor and In-Contact Transmission in Model Ferrets. Journal of virology, 90, 6235-6243.
  • Sullivan, S. P., D. G. Koutsonanos, M. del Pilar Martin, J. W. Lee, V. Zarnitsyn, S.-O. Choi, N. Murthy, R. W. Compans, I. Skountzou and M. R. Prausnitz, 2010: Dissolving polymer microneedle patches for influenza vaccination. Nat. Med., 16, 915-920.
  • Suarez, D. L., 2012: DIVA vaccination strategies for avian influenza virus. Avian diseases, 56, 836-844.
  • Suarez, D. L., 2005: Overview of avian influenza DIVA test strategies. Biologicals : journal of the International Association of Biological Standardization, 33, 221-226.
  • Starick, E., O. Werner, H. Schirrmeier, B. Kollner, R. Riebe and E. Mundt, 2006: Establishment of a competitive ELISA (cELISA) system for the detection of influenza A virus nucleoprotein antibodies and its application to field sera from different species. Journal of veterinary medicine. B, Infectious diseases and veterinary public health, 53, 370-375.
  • Spackman, E., D. A. Senne, L. L. Bulaga, T. J. Myers, M. L. Perdue, L. P. Garber, K. Lohman, L. T. Daum and D. L. Suarez, 2003: Development of real-time RTPCR for the detection of avian influenza virus. Avian diseases, 47, 1079- 1082.
  • Song, J.-M., Y.-C. Kim, O. Eunju, R. W. Compans, M. R. Prausnitz and S.-M. Kang, 2012: DNA vaccination in the skin using microneedles improves protection against influenza. Mol. Ther., 20, 1472-1480.
  • Singh, M. and D. O'Hagan, 1999: Advances in vaccine adjuvants. Nat. Biotechnol., 17, 1075-1081.
  • Shin, J.-H., J.-K. Park, D.-H. Lee, F.-S. Quan, C.-S. Song and Y.-C. Kim, 2015: Microneedle vaccination elicits superior protection and antibody response over intranasal vaccination against swine-origin influenza A (H1N1) in mice. PloS one, 10, e0130684.
  • Shen, H., C. Xue, L. Lv, W. Wang, Q. Liu, K. Liu, X. Chen, J. Zheng, X. Li and Y. Cao, 2013: Assembly and immunological properties of a bivalent virus-like particle (VLP) for avian influenza and Newcastle disease. Virus research, 178, 430-436.
  • Shafer, A. L., J. B. Katz and K. A. Eernisse, 1998: Development and validation of a competitive enzyme-linked immunosorbent assay for detection of type A influenza antibodies in avian sera. Avian diseases, 42, 28-34.
  • Senne, D. A., D. J. King and D. R. Kapczynski, 2004: Control of Newcastle disease by vaccination. Developments in biologicals, 119, 165-170.
  • Schrauwen, E. J. and R. A. Fouchier, 2014: Host adaptation and transmission of influenza A viruses in mammals. Emerging microbes & infections, 3, e9.
  • Schipper, P., K. van der Maaden, S. Romeijn, C. Oomens, G. Kersten, W. Jiskoot and J. Bouwstra, 2016: Determination of Depth-Dependent Intradermal Immunogenicity of Adjuvanted Inactivated Polio Vaccine Delivered by Microinjections via Hollow Microneedles. Pharm. Res., 1-11.
  • SWAYNE, D. E. 2008. Avian influenza. 1st edition. Blackwell Pub., Ames, Iowa xvi, 605 p., 604 p. of plates pp.
  • Roldao, A., M. C. Mellado, L. R. Castilho, M. J. Carrondo and P. M. Alves, 2010: Virus-like particles in vaccine development. Expert review of vaccines, 9, 1149-1176.
  • Raphael, A. P., T. W. Prow, M. L. Crichton, X. Chen, G. J. Fernando and M. A. Kendall, 2010: Targeted, Needle-Free Vaccinations in Skin using Multilayered, Densely-Packed Dissolving Microprojection Arrays. Small, 6, 1785-1793.
  • Quan, F.-S., C. Huang, R. W. Compans and S.-M. Kang, 2007: Virus-like particle vaccine induces protective immunity against homologous and heterologous strains of influenza virus. J. Virol., 81, 3514-3524.
  • Qiu, Y., L. Guo, S. Zhang, B. Xu, Y. Gao, Y. Hu, J. Hou, B. Bai, H. Shen and P. Mao, 2015: DNA-based vaccination against hepatitis B virus using dissolving microneedle arrays adjuvanted by cationic liposomes and CpG ODN. Drug Deliv.
  • Pearton, M., S.-M. Kang, J.-M. Song, Y.-C. Kim, F.-S. Quan, A. Anstey, M. Ivory, M. R. Prausnitz, R. W. Compans and J. C. Birchall, 2010: Influenza virus-like particles coated onto microneedles can elicit stimulatory effects on Langerhans cells in human skin. Vaccine, 28, 6104-6113.
  • Park, J. K., D. H. Lee, S. S. Yuk, E. O. Tseren-Ochir, J. H. Kwon, J. Y. Noh, B. Y. Kim, S. W. Choi, S. M. Kang, J. B. Lee, S. Y. Park, I. S. Choi and C. S. Song, 2014: Virus-like particle vaccine confers protection against a lethal newcastle disease virus challenge in chickens and allows a strategy of differentiating infected from vaccinated animals. Clinical and vaccine immunology : CVI, 21, 360-365.
  • Paepenm ller, T. and C. M ller-Goymann, 2014: Influence of Quil A on liposomal membranes. Int. J. Pharm., 475, 138-146.
  • Ohmit, S. E., J. G. Petrie, R. T. Cross, E. Johnson and A. S. Monto, 2011: Influenza hemagglutination-inhibition antibody titer as a correlate of vaccine-induced protection. J. Infect. Dis., jir661.
  • Neumann, G., H. Chen, G. F. Gao, Y. Shu and Y. Kawaoka, 2010: H5N1 influenza viruses: outbreaks and biological properties. Cell research, 20, 51-61.
  • Neumann, G. and Y. Kawaoka, 2015: Transmission of influenza A viruses. Virology, 479-480, 234-246.
  • Miura, T., N. Ohno, N. Miura, Y. Adachi, S. Shimada and T. Yadomae, 1999: Antigen-specific response of murine immune system toward a yeast β- glucan preparation, zymosan. FEMS Immunol. Med. Microbiol., 24, 131- 139.
  • Mc, L. M., W. Priyono, B. Bett, S. Al-Qamar, I. Claassen, T. Widiastuti, J. Poole, L. Schoonman, C. Jost and J. Mariner, 2015: Antibody response and risk factors for seropositivity in backyard poultry following mass vaccination against highly pathogenic avian influenza and Newcastle disease in Indonesia. Epidemiology and infection, 143, 1632-1642.
  • Mbow, M. L., E. De Gregorio and J. B. Ulmer, 2011: Alum's adjuvant action: grease is the word. Nat. Med., 17, 415-416.
  • Lv, L., X. Li, G. Liu, R. Li, Q. Liu, H. Shen, W. Wang, C. Xue and Y. Cao, 2014: Production and immunogenicity of chimeric virus-like particles containing the spike glycoprotein of infectious bronchitis virus. Journal of veterinary science, 15, 209-216.
  • Lu, N.-n., Q. Liu, L.-g. Gu, S.-j. Ge, J. Wu, Q. Ze-ji, Z.-j. Qiu, H.-c. Zhang, E.-x. Chao and Z.-n. Yu, 2014: Gene expression profiles underlying selective Tcell- mediated immunity activity of a Chinese medicine granule on mice infected with influenza virus H1N1. Evid. Based Complement. Alternat. Med., 2014.
  • Liu, Q., I. Mena, J. Ma, B. Bawa, F. Krammer, Y. S. Lyoo, Y. Lang, I. Morozov, G. N. Mahardika, W. Ma, A. Garcia-Sastre and J. A. Richt, 2015: Newcastle Disease Virus-Vectored H7 and H5 Live Vaccines Protect Chickens from Challenge with H7N9 or H5N1 Avian Influenza Viruses. Journal of virology, 89, 7401-7408.
  • Li, T. C., Y. Yamakawa, K. Suzuki, M. Tatsumi, M. A. Razak, T. Uchida, N. Takeda and T. Miyamura, 1997: Expression and self-assembly of empty virus-like particles of hepatitis E virus. Journal of virology, 71, 7207-7213.
  • Li, M., N. Zhao, J. Luo, Y. Li, L. Chen, J. Ma, L. Zhao, G. Yuan, C. Wang, Y. Wang, Y. Liu and H. He, 2017: Genetic Characterization of Continually Evolving Highly Pathogenic H5N6 Influenza Viruses in China, 2012-2016. Frontiers in microbiology, 8, 260.
  • Lee, E. K., B. M. Song, Y. N. Lee, G. B. Heo, Y. C. Bae, S. J. Joh, S. C. Park, K. S. Choi, H. J. Lee, I. Jang, M. S. Kang, O. M. Jeong, B. K. Choi, S. M. Lee, S. C. Jeong, B. K. Park, H. S. Lee and Y. J. Lee, 2017b: Multiple novel H5N6 highly pathogenic avian influenza viruses, South Korea, 2016. Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases, 51, 21-23.
  • Lee, D. H., M. K. Torchetti, M. L. Killian, T. J. DeLiberto and D. E. Swayne, 2017a: Reoccurrence of Avian Influenza A(H5N2) Virus Clade 2.3.4.4 in Wild Birds, Alaska, USA, 2016. Emerging infectious diseases, 23, 365-367.
  • Lee, D. H., M. K. Torchetti, K. Winker, H. S. Ip, C. S. Song and D. E. Swayne, 2015: Intercontinental Spread of Asian-Origin H5N8 to North America through Beringia by Migratory Birds. Journal of virology, 89, 6521-6524.
  • Lee, D. H., J. K. Park, J. H. Kwon, S. S. Yuk, T. O. Erdene-Ochir, Y. H. Jang, B. L. Seong, J. B. Lee, S. Y. Park, I. S. Choi and C. S. Song, 2013: Efficacy of single dose of a bivalent vaccine containing inactivated Newcastle disease virus and reassortant highly pathogenic avian influenza H5N1 virus against lethal HPAI and NDV infection in chickens. PloS one, 8, e58186.
  • Lee, D. H., J. K. Park and C. S. Song, 2014: Progress and hurdles in the development of influenza virus-like particle vaccines for veterinary use. Clinical and experimental vaccine research, 3, 133-139.
  • Kwon, J. H., D. H. Lee, D. E. Swayne, J. Y. Noh, S. S. Yuk, T. O. Erdene-Ochir, W. T. Hong, J. H. Jeong, S. Jeong, G. B. Gwon, S. Lee and C. S. Song, 2017: Reassortant Clade 2.3.4.4 Avian Influenza A(H5N6) Virus in a Wild Mandarin Duck, South Korea, 2016. Emerging infectious diseases, 23, 822- 826.
  • Kumar, A., J. Zhang and F. S. X. Yu, 2006: Toll-like receptor 3 agonist poly (I: C)- induced antiviral response in human corneal epithelial cells. Immunology, 117, 11-21.
  • Ko, Y.-T. and Y.-L. Lin, 2004: 1, 3-β-Glucan quantification by a fluorescence microassay and analysis of its distribution in foods. J. Agric. Food Chem., 52, 3313-3318.
  • Kim, Y.-C., J.-H. Park and M. R. Prausnitz, 2012: Microneedles for drug and vaccine delivery. Adv. Drug Del. Rev., 64, 1547-1568.
  • Kim, Y.-C., F.-S. Quan, R. W. Compans, S.-M. Kang and M. R. Prausnitz, 2010: Formulation and coating of microneedles with inactivated influenza virus to improve vaccine stability and immunogenicity. J. Controlled Release, 142, 187-195.
  • Kim, Y.-C., F.-S. Quan, D.-G. Yoo, R. W. Compans, S.-M. Kang and M. R. Prausnitz, 2009: Improved influenza vaccination in the skin using vaccine coated microneedles. Vaccine, 27, 6932-6938.
  • Kim, Y.-C., D.-G. Yoo, R. W. Compans, S.-M. Kang and M. R. Prausnitz, 2013: Cross-protection by co-immunization with influenza hemagglutinin DNA and inactivated virus vaccine using coated microneedles. J. Controlled Release, 172, 579-588.
  • Kim, Y. H. 2017: Understanding of host switch and host adaptation to the avian influenza virus. J Bacteriol Virol, 47(1), 14-31.
  • Kim, S. H., A. Paldurai, S. Xiao, P. L. Collins and S. K. Samal, 2014: Modified Newcastle disease virus vectors expressing the H5 hemagglutinin induce enhanced protection against highly pathogenic H5N1 avian influenza virus in chickens. Vaccine, 32, 4428-4435.
  • Keitel, W., N. Groth, M. Lattanzi, M. Praus, A. K. Hilbert, A. Borkowski and T. F. Tsai, 2010: Dose ranging of adjuvant and antigen in a cell culture H5N1 influenza vaccine: safety and immunogenicity of a phase 1/2 clinical trial. Vaccine, 28, 840-848.
  • Kalthoff, D., A. Giritch, K. Geisler, U. Bettmann, V. Klimyuk, H. R. Hehnen, Y. Gleba and M. Beer, 2010: Immunization with plant-expressed hemagglutinin protects chickens from lethal highly pathogenic avian influenza virus H5N1 challenge infection. Journal of virology, 84, 12002- 12010.
  • Jeong, J., C. Woo, H. S. Ip, I. An, Y. Kim, K. Lee, S. D. Jo, K. Son, S. Lee, J. K. Oem, S. J. Wang, Y. Kim, J. Shin, J. Sleeman and W. Jheong, 2017: Identification of Two novel reassortant avian influenza a (H5N6) viruses in whooper swans in Korea, 2016. Virology journal, 14, 60.
  • Horman, W. S. J., T. H. O. Nguyen, K. Kedzierska, A. G. D. Bean, Andd. S. Layton. 2018. The Drivers of Pathology in Zoonotic Avian Influenza: The Interplay Between Host and Pathogen. Front Immunol 9: 1812.
  • Hoffmann, E., J. Stech, Y. Guan, R. G. Webster and D. R. Perez, 2001: Universal primer set for the full-length amplification of all influenza A viruses. Archives of virology, 146, 2275-2289.
  • Hiraishi, Y., S. Nandakumar, S.-O. Choi, J. W. Lee, Y.-C. Kim, J. E. Posey, S. B. Sable and M. R. Prausnitz, 2011: Bacillus Calmette-Guerin vaccination using a microneedle patch. Vaccine, 29, 2626-2636.
  • Hickling, J. and R. Jones, 2009: Intradermal delivery of vaccines: a review of the literature and the potential for development for use in low-and middleincome countries. Program for Appropriate Technology in Health (PATH), Ferney Voltaire.
  • Guo, L., Y. Qiu, J. Chen, S. Zhang, B. Xu and Y. Gao, 2013: Effective transcutaneous immunization against hepatitis B virus by a combined approach of hydrogel patch formulation and microneedle arrays. Biomed. Microdevices, 15, 1077-1085.
  • Group, W. O. F. H. N. E. W., 2008: Toward a unified nomenclature system for highly pathogenic avian influenza virus (H5N1). Emerging infectious diseases, 14, e1.
  • Gill, H. S. and M. R. Prausnitz, 2007: Coated microneedles for transdermal delivery. J. Controlled Release, 117, 227-237.
  • Fujita, H., A. Asahina, H. Mitsui and K. Tamaki, 2004: Langerhans cells exhibit low responsiveness to double-stranded RNA. Biochem. Biophys. Res. Commun., 319, 832-839.
  • Frasnelli, M. E., D. Tarussio, V. Chobaz-P clat, N. Busso and A. So, 2005: TLR2 modulates inflammation in zymosan-induced arthritis in mice. Arthritis Res. Ther., 7, R370Gantner, B. N., R. M. Simmons, S. J. Canavera, S. Akira and D. M. Underhill, 2003: Collaborative induction of inflammatory responses by dectin-1 and Toll-like receptor 2. J. Exp. Med., 197, 1107-1117.
  • Fouchier, R., T. Kuiken, G. Rimmelzwaan and A. Osterhaus, 2005: Global task force for influenza. Nature, 435, 419-420.
  • Fang, C. F., M. J. MA, B. D. Zhan, S. M. Lai, Y. Hu, X. X. Yang, J. Li, G. P. Cao, J. J. Zhou, J. M. Zhang, S. Q. Wang, X. L. Hu, Y. J. Li, X. X. Wang, W. Cheng, H. W. Yao, X. L. Li, H. M. Yi, W. D. Xu, J. F. Jiang, G. C. Gray, L. Q. Fang, E. F. Chen, Andw. C. Cao. 2015. Nosocomial transmission of avian influenza A (H7N9) virus in China: epidemiological investigation. BMJ 351: h5765.
  • Donadei, A., S. Gallorini, F. Berti, D. T. O’Hagan, R. Adamo and B. C. Baudner, 2015: Rational design of adjuvant for skin delivery: conjugation of synthetic β-glucan Dectin-1 agonist to protein antigen. Mol. Pharm., 12, 1662-1672.
  • Ding, Z., F. J. Verbaan, M. Bivas-Benita, L. Bungener, A. Huckriede, D. J. van den Berg, G. Kersten and J. A. Bouwstra, 2009: Microneedle arrays for the transcutaneous immunization of diphtheria and influenza in BALB/c mice. J. Controlled Release, 136, 71-78.
  • Dillon, S., S. Agrawal, K. Banerjee, J. Letterio, T. L. Denning, K. Oswald-Richter, D. J. Kasprowicz, K. Kellar, J. Pare and T. van Dyke, 2006: Yeast zymosan, a stimulus for TLR2 and dectin-1, induces regulatory antigen-presenting cells and immunological tolerance. J. Clin. Invest., 116, 916-928.
  • Deo, V. K., T. Kato and E. Y. Park, 2015: Chimeric virus-like particles made using GAG and M1 capsid proteins providing dual drug delivery and vaccination platform. Molecular pharmaceutics, 12, 839-845.
  • Cowling, B. J., L. Jin, E. H. Lau, Q. Liao, P. Wu, H. Jiang, T. K. Tsang, J. Zheng, V. J. Fang, Z. Chang, M. Y. NI, Q. Zhang, D. K. IP, J. Yu, Y. Li, L. Wang, W. Tu, L. Meng, J. T. Wu, H. Luo, Q. Li, Y. Shu, Z. Li, Z. Feng, W. Yang, Y. Wang, G. M. Leung, Andh. Yu. 2013. Comparative epidemiology of human infections with avian influenza A H7N9 and H5N1 viruses in China: a population-based study of laboratory-confirmed cases. Lancet 382: 129-137.
  • Buxton Bridges, C., J. M. Katz, W. H. Seto, P. K. Chan, D. Tsang, W. Ho K. H. Mak, W. Lim, J. S. Tam, M. Clarke, S. G. Williams, A. W. Mounts, J. S. Bresee, L. A. Conn, T. Rowe, J. Hu-Primmer, R. A. Abernathy, X. Lu, N. J. Cox, Andk. Fukuda. 2000. Risk of influenza A (H5N1) infection among health care workers exposed to patients with influenza A (H5N1), Hong Kong. J Infect Dis 181: 344-348.
  • Buonaguro, L., M. L. Tornesello, M. Tagliamonte, R. C. Gallo, L. X. Wang, R. Kamin-Lewis, S. Abdelwahab, G. K. Lewis and F. M. Buonaguro, 2006: Baculovirus-derived human immunodeficiency virus type 1 virus-like particles activate dendritic cells and induce ex vivo T-cell responses. Journal of virology, 80, 9134-9143.
  • Brown, L. E., 2010: The role of adjuvants in vaccines for seasonal and pandemic influenza. Vaccine, 28, 8043-8045.
  • Brown, C., D. J. King and B. S. Seal, 1999: Pathogenesis of Newcastle disease in chickens experimentally infected with viruses of different virulence. Veterinary pathology, 36, 125-132.
  • Bi, Y., Q. Chen, Q. Wang, J. Chen, T. Jin, G. Wong, C. Quan, J. Liu, J. Wu, R. Yin, L. Zhao, M. Li, Z. Ding, R. Zou, W. Xu, H. Li, H. Wang, K. Tian, G. Fu, Y. Huang, A. Shestopalov, S. Li, B. Xu, H. Yu, T. Luo, L. Lu, X. Xu, Y. Luo, Y. Liu, W. Shi, D. Liu and G. F. Gao, 2016: Genesis, Evolution and Prevalence of H5N6 Avian Influenza Viruses in China. Cell Host Microbe, 20, 810-821.
  • Baumgarth, N., L. Brown, D. Jackson and A. Kelso, 1994: Novel features of the respiratory tract T-cell response to influenza virus infection: lung T cells increase expression of gamma interferon mRNA in vivo and maintain high levels of mRNA expression for interleukin-5 (IL-5) and IL-10. J. Virol., 68, 7575-7581.
  • Bal, S. M., Z. Ding, G. F. Kersten, W. Jiskoot and J. A. Bouwstra, 2010: Microneedle-based transcutaneous immunisation in mice with N-trimethyl chitosan adjuvanted diphtheria toxoid formulations. Pharm. Res., 27, 1837- 1847.
  • Bachy, V., C. Hervouet, P. D. Becker, L. Chorro, L. M. Carlin, S. Herath, T. Papagatsias, J.-B. Barbaroux, S.-J. Oh and A. Benlahrech, 2013: Langerin negative dendritic cells promote potent CD8+ T-cell priming by skin delivery of live adenovirus vaccine microneedle arrays. Proc. Natl. Acad. Sci. U. S. A., 110, 3041-3046.
  • Ara, Y., T. Saito, T. Takagi, E. Hagiwara, Y. Miyagi, M. Sugiyama, S. Kawamoto, N. Ishii, T. Yoshida and D. Hanashi, 2001: Zymosan enhances the immune response to DNA vaccine for human immunodeficiency virus type-1 through the activation of complement system. Immunology, 103, 98-105.
  • Andrianov, A. K., D. P. DeCollibus, H. A. Gillis, H. K. Henry, A. Marin, M. R. Prausnitz, L. A. Babiuk, H. Townsend and G. Mutwiri, 2009: Poly [di (carboxylatophenoxy) phosphazene] is a potent adjuvant for intradermal immunization. Proc. Natl. Acad. Sci. U. S. A., 106, 18936-18941.
  • Alexander, D. J., 2001: Gordon Memorial Lecture. Newcastle disease. British poultry science, 42, 5-22.
  • Alexander, D. J., 2000b: A review of avian influenza in different bird species. Veterinary microbiology, 74, 3-13.
  • Alexander, D. J., 2000a: Newcastle disease and other avian paramyxoviruses. Revue scientifique et technique, 19, 443-462.
  • Ainai, A., T. Ichinohe, S. i. Tamura, T. Kurata, T. Sata, M. Tashiro and H. Hasegawa, 2010: Zymosan enhances the mucosal adjuvant activity of poly (I: C) in a nasal influenza vaccine. J. Med. Virol., 82, 476-484.